Franklin, Reuben http://orcid.org/0000-0002-6513-3205
Guo, Yiming
He, Shiyang http://orcid.org/0000-0002-1849-2635
Chen, Meijuan http://orcid.org/0000-0001-6200-9404
Ji, Fei
Zhou, Xinyue
Frankhouser, David http://orcid.org/0000-0002-8233-5853
Do, Brian T. http://orcid.org/0000-0003-4992-2623
Chiem, Carmen
Jang, Mihyun
Blanco, M. Andres
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Rockne, Russell C. http://orcid.org/0000-0002-1557-159X
Ninova, Maria http://orcid.org/0000-0001-5051-5502
Sykes, David B.
Hochedlinger, Konrad http://orcid.org/0000-0001-5811-5386
Lu, Rui http://orcid.org/0000-0003-1593-2612
Sadreyev, Ruslan I.
Murn, Jernej http://orcid.org/0000-0002-1729-5859
Volk, Andrew http://orcid.org/0000-0003-2133-7940
Cheloufi, Sihem http://orcid.org/0000-0002-1726-4796
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142452)
U.S. Department of Defense (CA 120212)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (5R01HD058013-10)
City of Hope/UCR biomedical research initiative UC cancer research coordinating committee
Article History
Received: 23 November 2020
Accepted: 25 March 2022
First Online: 29 April 2022
Competing interests
: M.G.V.H. discloses that he is an advisor for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, DROIA Ventures, and Auron Therapeutics. D.B.S. is a co-founder and holds equity in Clear Creek Bio and is a consultant and holds equity in SAFI Biosolutions. The remaining authors declare no competing interests.